Search results
Vladimir MOISEYENKO | Cited by 9,668 | of National Cancer Institute Thailand, Bangkok (NCI) | Read 112 publications | Contact Vladimir MOISEYENKO
Jun 4, 2017 · We did a randomised, double-blind, active-controlled, phase 3 trial to establish the equivalence of CT-P6 to reference trastuzumab in terms of efficacy in patients with HER2-positive, operable, early-stage breast cancer treated in the neoadjuvant setting.
- Justin Stebbing, Yauheni Baranau, Valeriy Baryash, Alexey Manikhas, Vladimir Moiseyenko, Giorgi Dzag...
- 2017
Feb 8, 2022 · Moiseyenko reports receiving personal fees from AstraZeneca and Merck; receiving grants from AstraZeneca, BIOCAD Bristol-Myers Squibb, Merck Sharp & Dohme, Roche, and Servier; and having a leadership role with the Russian Society of Clinical Oncology.
Apr 9, 2020 · A supportive analysis for OS in patients with PD-L1 TC ≥25% showed a restricted mean survival time difference of 1.99 months (95% CI, −0.37 to 4.35) for durvalumab vs chemotherapy and 0.76 months (95% CI, −1.62 to 3.14) for durvalumab plus tremelimumab vs chemotherapy.
- Naiyer A Rizvi, Byoung Chul Cho, Niels Reinmuth, Ki Hyeong Lee, Alexander Luft, Myung-Ju Ahn, Michel...
- 10.1001/jamaoncol.2020.0237
- 2020
- JAMA Oncol. 2020 May; 6(5): 661-674.
- Implications For Practice
- Introduction
- Methods
- Results
- Discussion
- Conclusion
- Acknowledgments
- Author Contributions
- Disclosures
Two surveys were conducted to evaluate the global use of biomarkers in clinical practice and the largely unreported patient experience of precision medicine. These findings are especially relevant because they address both self-reported and physician-assessed levels of patients’ “cancer literacy.” This unique opportunity allowed for identification ...
Recent initiatives to encourage the development of useful and accurate biomarkers have highlighted the role of personalized care as an increasingly important tool in modern medicine . Identification of tumor-specific alterations, such as DNA point mutations, amplifications, and translocations, can help determine a patient’s prognosis or predict how...
Patient Survey
Between September and December 2011, interviews of patients with breast cancer, NSCLC, and mCRC were conducted via 15-minute telephone surveys. Interviews were conducted in Argentina, China, France, Germany, Italy, Spain, and the U.K. by a maximum of five interviewers per region. Ipsos (Paris, France, http://www.ipsos.com) identified patients by their physicians and patient associations; in Spain, patients were contacted only through patient associations. To help identify appropriate patients...
Physician Survey
Interviews with physicians were conducted via 10-minute online interviews between October and December 2013. Countries included in the survey were as follows: Argentina, Brazil, China, France, Germany, Italy, Japan, Russia, Saudi Arabia, Spain, Turkey, and the U.K. Physicians were recruited via Ipsos. Eligible physicians had 3–35 years of experience in their current specialty, were involved in the day-to-day management of patients with cancer, and saw at least 15 patients per month. Physician...
Characteristics of Surveyed Physicians and Patients
As stated earlier, patients and physicians from Argentina, China, France, Germany, Italy, Spain, and the U.K. were surveyed. In addition, physicians from Brazil, Japan, Russia, Saudi Arabia, and Turkey were interviewed (Table 1). Patients had been diagnosed with NSCLC (19.4%), breast cancer (20.2%), or mCRC (60.4%; Table 1). Physicians were categorized as specialists in NSCLC (22.2%), breast cancer (34.6%), or mCRC (43.1%) according to their highest patient caseload (Table 1). Physicians desc...
Patients’ Understanding of Tumor Biology and the Principle of Precision Medicine
Patients were asked questions to assess their understanding of cancer biology and precision medicine. Physicians were asked to evaluate how they believed their patients would answer the same or similar questions. Nearly half (49%) of the surveyed patients correctly identified that different types of cancer can affect a single organ and that the types of cancer affecting one organ are different from those affecting other organs. Similarly, most physicians believed that patients understood this...
Patient Willingness to Consider Biomarker Testing
More than half of patients (66%) reported willingness to delay treatment to allow for additional tumor testing, but this was overestimated by physicians, 82% of whom believed that their patients would be willing to delay (Fig. 2A). Interestingly, physicians underestimated the amount of time that patients would be willing to delay treatment to undergo testing, with 22% of patients reporting that they would wait as long as a month and 32% reporting that they would delay as long as it takes. In...
Progress in the development and establishment of molecular tests to inform the personalization of anticancer therapy is intrinsically linked to the analysis of human tissue samples. Therefore, for testing to begin, patients with cancer must understand the nature of the research and provide their consent for their tissues and clinical data to be use...
Patients and physicians were generally aware of the advances in precision medicine and showed willingness to participate in associated biomarker testing. However, considerable opportunity remains for physicians and support groups to better educate patients about the ability of biomarker testing to inform the most effective, personalized treatment s...
We acknowledge medical writing assistance provided by Meghan Sullivan of ClinicalThinking, Hamilton, New Jersey, which was funded by Merck KGaA.
Conception/Design:Fortunato Ciardiello, Richard Adams, Josep Tabernero, Thomas Seufferlein, Julien Taieb, Vladimir Moiseyenko, Brigette Ma, Gustavo Lopez, Johan F. Vansteenkiste, Sabine Tejpar Provision of study material or patients:Fortunato Ciardiello, Richard Adams, Josep Tabernero, Thomas Seufferlein, Julien Taieb, Vladimir Moiseyenko, Brigette...
Fortunato Ciardiello: Merck KGaA, Bayer, Roche, Astellas, Lilly (C/A), Bayer, Astra Zeneca (RF); Richard Adams: Merck Serono (C/A, ET); Josep Tabernero: Amgen, Boehringer, Celgene, Chugai, Imclone, Lilly, Merck, Merck Serono, Millennium, Novartis, Roche, Sanofi, Symphogen, Taiho (C/A); Thomas Seufferlein: Merck Serono, Roche, Amgen (C/A, H); Julien...
- Ciardiello, Fortunato
Jan 1, 2023 · Methods. Eligible patients with EGFR and ALK wild-type mNSCLC were randomized (1:1) to first-line durvalumab (20 mg/kg every 4 weeks until progression) plus tremelimumab (1 mg/kg every 4 weeks for up to four doses) or standard chemotherapy. Randomization was stratified by tumor programmed death-ligand 1 expression (≥25% versus <25%), tumor ...
NEPTUNE, a phase 3, open-label study, evaluated first-line durvalumab plus tremelimumab versus chemotherapy in metastatic NSCLC (mNSCLC). (20 mg/kg every 4 weeks until progression) plus trem-elimumab (1 mg/kg every 4 weeks for up to four doses) or standard chemotherapy. Randomization was strati ed by.
